A paper that can estimate the effectiveness of the anticancer virus Pexa-Vec, which is being developed by ShillaJen, has been published.
Sillajen announced that the clinical results of the ‘Pexa-Vec preoperative therapy (adjuvant therapy through intravenous administration prior to surgery)’ conducted by Transgene, a European partner, in 9 patients with metastatic colorectal cancer (CRLM) and metastatic melanoma scheduled for surgery in the U.S. national It was announced on the 26th that it was recently published on the medical article search site (Pubmed) operated by the Center for Biotechnology Information (NCBI).
The clinical trial was conducted from September 2015 to June 2018, and it was designed as a neoadjuvant intravenous administration of Pexa-Vec once before surgery.
Eight out of nine patients underwent surgery as scheduled, and as a result of histopathological analysis of cancer tissue, CR (complete response) and PR (partial response) were counted in one each.
As a result of long-term follow-up of the patient, as of the time the thesis was written (around December 2021), 5 out of 9 patients survived, and 3 patients with CRLM showed complete remission.
In particular, in the case of one 47-year-old CRLM patient who received Pexa-Vec in the presence of both primary and metastatic cancer, surgery was canceled after pre-treatment with Pexa-Vec, but it is said that he is still alive.
The research team explained, “After administration of Pexa-Vec, patients with greatly increased T lymphocyte diversity are surviving for a long time. This means the formation of memory cells for cancer antigens.”
A large number of oncology virus experts such as Dr. Richard G Weil, an authority on overseas cancer research, participated in this study. The University of Leeds in the UK and the London Cancer Institute, the Ontario Institute in Canada and the Mayo Clinic in the US were also included.
On the other hand, ShillaJen welcomed M2N as the new largest shareholder in July 2021, and is spurring the normalization of management after receiving a six-month improvement period from the KOSDAQ Market Committee in February.
Send articles on social media
